# PharmaLegacy

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmalegacy

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.pharmalegacy.com
- Latest round: Series A (Feb 2, 2019)
- Investors on record: 3

## About

Based in Shanghai and established in 2008, PharmaLegacy is an comprehensive pre-clinical biomedical research and development service company that focuses on providing conforming country international standard pharmacological pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology and three types of medical device evaluation research services. It has 10000 square meter laboratory,of which 4000 square meter is animal vivarium that is accredited by AAALAC and house 10,000 rodents and large animals, and on-site capacity for up to 350 non-human primates. In February 2025, Shanghai OPM Biosciences announced to fully acquire PharmaLegacy.

The company provides complete preclinical pharmacology services for early proof-of-concept of therapeutics and fulfillment of regulatory requirements. Specific services include oncology platform, non-human primates platform, inflammation and autoimmune diseases model, bone and orthopedics, respiratory diseases model, histopathology, metabolic and liver and cardiovascular diseases model.

The company generates revenue by providing preclinical pharmacology services.

## Funding rounds

- Series A, Feb 2, 2019 — Prosperico Ventures
- Series A, Jan 3, 2017 — Tigermed, Prosperico Ventures, Sutter Rock Capital

## Investors

- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series A
- Sutter Rock Capital (https://capitalatlas.ai/funds/sutter-rock-capital) — Series A